SEC Filings

Form S-1/A
VITAE PHARMACEUTICALS, INC filed this Form S-1/A on 08/28/2014
Document Outline
Entire Document (4676 KB)
Subdocument 1 - S-1/A - S-1/A
Page 1 - As filed with the Securities and Exchange Commission on August 27, 2014
Page 2 - Preliminary Prospectus
Page 3 - TABLE OF CONTENTS
Page 4 - PROSPECTUS SUMMARY
Page 5 - Our Most Advanced Product Candidates
Page 6 - VTP-43742
Page 7 - Our Collaborations
Page 8 - Intellectual Property
Page 9 - Corporate Information
Page 10 - N/A
Page 11 - The Offering
Page 12 - N/A
Page 13 - SUMMARY FINANCIAL DATA
Page 14 - N/A
Page 15 - RISK FACTORS
Page 16 - We will require substantial additional financing to achieve our goals, and a failure to obtain this
Page 17 - Raising additional capital may cause dilution to our existing stockholders, restrict our operations
Page 18 - Our ability to use net operating loss and tax credit carryforwards and certain built-in losses to re
Page 19 - Risks Related to the Clinical Development and Regulatory Approval of Our Product Candidates
Page 20 - Clinical failure may occur at any stage of clinical development, and because our product candidates
Page 21 - If we or our partners fail to obtain regulatory approval in jurisdictions outside the United States,
Page 22 - We and BI rely on third parties to conduct preclinical studies and clinical trials for our product c
Page 23 - We intend to rely on third-party manufacturers, including BI with respect to VTP-34072 and VTP-37948
Page 24 - We may not be successful in establishing and maintaining additional strategic partnerships, which co
Page 25 - N/A
Page 26 - Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecut
Page 27 - Third-party claims of intellectual property infringement or misappropriation may prevent or delay ou
Page 28 - We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, wh
Page 29 - We may need to license certain intellectual property from third parties, and such licenses may not b
Page 30 - Our reliance on third parties requires us to share our trade secrets, which increases the possibilit
Page 31 - If we do not obtain protection under the Hatch-Waxman Amendments by extending the patent terms and o
Page 32 - Coverage and reimbursement may be limited or unavailable in certain market segments for our product
Page 33 - The impact of recent healthcare reform legislation and other changes in the healthcare industry and
Page 34 - We face substantial competition, which may result in others discovering, developing or commercializi
Page 35 - Our product candidates may cause undesirable side effects or have other properties that delay or pre
Page 36 - Risks Related to Our Business and Industry
Page 37 - Our employees, independent contractors, principal investigators, CROs, consultants, commercial partn
Page 38 - N/A
Page 39 - We may encounter difficulties in managing our growth and expanding our operations successfully.
Page 40 - If product liability lawsuits are brought against us, we may incur substantial liabilities and may b
Page 41 - Our internal computer systems, or those of our development partners, third-party clinical research o
Page 42 - Risks Related to Our Common Stock and this Offering
Page 43 - Our quarterly operating results may fluctuate significantly.
Page 44 - You will suffer immediate and substantial dilution in the net tangible book value of the common stoc
Page 45 - We do not intend to pay dividends on our common stock, and, consequently, your ability to achieve a
Page 46 - We are an emerging growth company, and the reduced reporting requirements applicable to emerging gro
Page 47 - Because a small number of our existing stockholders own a majority of our voting stock, your ability
Page 48 - N/A
Page 49 - INFORMATION REGARDING FORWARD-LOOKING STATEMENTS
Page 50 - INDUSTRY AND MARKET DATA
Page 51 - USE OF PROCEEDS
Page 52 - DIVIDEND POLICY
Page 53 - CAPITALIZATION
Page 54 - N/A
Page 55 - DILUTION
Page 56 - N/A
Page 57 - SELECTED FINANCIAL DATA
Page 58 - N/A
Page 59 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF
Page 60 - Strategic Partnerships
Page 61 - B-site Amyloid Precursor Protein-Cleaving Enzyme Inhibitors with BI
Page 62 - Financial Operations Overview
Page 63 - Milestone Revenue
Page 64 - N/A
Page 65 - RORgt
Page 66 - Contour and Technology Development
Page 67 - Revenue Recognition
Page 68 - Accrued Clinical and Preclinical Expenses
Page 69 - Stock-Based Compensation
Page 70 - Valuation of Privately-Held-Company Equity Securities Issued as Compensation
Page 71 - Results of Operations
Page 72 - General and Administrative.
Page 73 - General and Administrative.
Page 74 - Cash Flows
Page 75 - Comparison of Years Ended December 31, 2013 and 2012
Page 76 - Plan of Operation
Page 77 - Contractual Obligations and Commitments
Page 78 - Recently Adopted Accounting Standards
Page 79 - BUSINESS
Page 80 - N/A
Page 81 - in vivo
Page 82 - Our Strategy
Page 83 - Continue investing in technology, people and intellectual property.
Page 84 - Cortisol in Metabolic Disease
Page 85 - Market Opportunity
Page 86 - Preclinical Data
Page 87 - VTP-37948 Targeting b-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE) for Alzheimer's Diseas
Page 88 - BACE as a Target in Alzheimer's Disease
Page 89 - Market Opportunity
Page 90 - Figure 5: Rats brain tissue assayed for levels of Ab and concentrations of VTP-37948. The various sy
Page 91 - IL-17 and Th17 Cells in Autoimmunity
Page 92 - RORgt as a Target in Autoimmunity
Page 93 - Market Opportunity
Page 94 - Human Whole Blood Assay
Page 95 - Left
Page 96 - Development Plans
Page 97 - Inflammation in ACS
Page 98 - Market Opportunity
Page 99 - ABCA1 mRNA in Human Skin Fibroblasts
Page 100 - Figure 17: Cynomolgus monkeys were dosed once-a-day for 14 days with VTP-38443. Levels of mRNA for A
Page 101 - Development Plans
Page 102 - Figure 19: Depiction of the composition and architecture of the epidermis.
Page 103 - Preclinical Data
Page 104 - Figure 21: VTP-38543 induced genes critical for lipid transport and lipid synthesis in skin.
Page 105 - Inhibition of IL-6 Secretion by THP-1 Macrophages
Page 106 - Immuno-Oncology Program
Page 107 - Contour Discovery Process
Page 108 - de novo
Page 109 - Figure 27: Time to develop a novel chemistry solution and achieve animal proof-of-concept.
Page 110 - N/A
Page 111 - BACE
Page 112 - Intellectual Property
Page 113 - LXRb Acute Coronary Syndrome:
Page 114 - Manufacturing
Page 115 - Commercialization
Page 116 - Phase 1.
Page 117 - N/A
Page 118 - Post-approval Requirements
Page 119 - Regulation Outside of the United States
Page 120 - N/A
Page 121 - Coverage and Reimbursement
Page 122 - Employees
Page 123 - Property and facilities
Page 124 - MANAGEMENT
Page 125 - Peter Barrett, Ph.D.
Page 126 - Charles W. Newhall, III
Page 127 - Code of Business Conduct and Ethics
Page 128 - Compensation Committee
Page 129 - Nominating and Governance Committee
Page 130 - Non-Employee Director Compensation
Page 131 - EXECUTIVE COMPENSATION
Page 132 - Equity Compensation
Page 133 - Outstanding Equity Awards as of December 31, 2013
Page 134 - N/A
Page 135 - Severance Benefits
Page 136 - Retirement Benefits
Page 137 - Letter Agreement with New Chief Business Officer
Page 138 - Administration.
Page 139 - Corporate Transactions.
Page 140 - Changes in Capitalization.
Page 141 - Administration.
Page 142 - Changes in Capitalization.
Page 143 - Changes in Capitalization.
Page 144 - Administration.
Page 145 - 2014 Employee Stock Purchase Plan
Page 146 - CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Page 147 - Employment Agreements
Page 148 - PRINCIPAL STOCKHOLDERS
Page 149 - N/A
Page 150 - N/A
Page 151 - N/A
Page 152 - DESCRIPTION OF CAPITAL STOCK
Page 153 - Options
Page 154 - Anti-takeover Effects of Delaware Law and Our Restated Certificate of Incorporation and Bylaws
Page 155 - Limitation of Liability and Indemnification Matters
Page 156 - SHARES ELIGIBLE FOR FUTURE SALE
Page 157 - Rule 701
Page 158 - MATERIAL UNITED STATES TAX CONSIDERATIONS TO NON-U.S. HOLDERS
Page 159 - Distributions on Our Common Stock
Page 160 - U.S. Federal Estate Tax
Page 161 - N/A
Page 162 - UNDERWRITING
Page 163 - Commissions and Discounts
Page 164 - N/A
Page 165 - NASDAQ Market Listing
Page 166 - Discretionary Sales
Page 167 - Notice to Residents of the United Kingdom
Page 168 - Notice to Residents of the Netherlands
Page 169 - N/A
Page 170 - LEGAL MATTERS
Page 171 - VITAE PHARMACEUTICALS, INC.
Page 172 - Report of Independent Registered Public Accounting Firm
Page 173 - Balance Sheets
Page 174 - Statements of Operations
Page 175 - Statements of Comprehensive Income
Page 176 - Vitae Pharmaceuticals, Inc.
Page 177 - Statements of Cash Flows
Page 178 - 1. Organization
Page 179 - Notes to the Financial Statements (Continued)
Page 180 - Notes to the Financial Statements (Continued)
Page 181 - Notes to the Financial Statements (Continued)
Page 182 - Notes to the Financial Statements (Continued)
Page 183 - Notes to the Financial Statements (Continued)
Page 184 - Notes to the Financial Statements (Continued)
Page 185 - Notes to the Financial Statements (Continued)
Page 186 - Notes to the Financial Statements (Continued)
Page 187 - Notes to the Financial Statements (Continued)
Page 188 - Notes to the Financial Statements (Continued)
Page 189 - Notes to the Financial Statements (Continued)
Page 190 - Notes to the Financial Statements (Continued)
Page 191 - Notes to the Financial Statements (Continued)
Page 192 - Notes to the Financial Statements (Continued)
Page 193 - Notes to the Financial Statements (Continued)
Page 194 - Notes to the Financial Statements (Continued)
Page 195 - Notes to the Financial Statements (Continued)
Page 196 - Notes to the Financial Statements (Continued)
Page 197 - Notes to the Financial Statements (Continued)
Page 198 - Notes to the Financial Statements (Continued)
Page 199 - Notes to the Financial Statements (Continued)
Page 200 - Notes to the Financial Statements (Continued)
Page 201 - Notes to the Financial Statements (Continued)
Page 202 - Notes to the Financial Statements (Continued)
Page 203 - Condensed Balance Sheets
Page 204 - Unaudited Condensed Statements of Operations
Page 205 - Unaudited Condensed Statements of Comprehensive Loss
Page 206 - Unaudited Condensed Statements of Cash Flows
Page 207 - Notes to Unaudited Condensed Financial Statements
Page 208 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 209 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 210 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 211 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 212 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 213 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 214 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 215 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 216 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 217 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 218 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 219 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 220 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 221 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 222 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 223 - Shares
Page 224 - PART II
Page 225 - Item 15. Recent Sales of Unregistered Securities
Page 226 - Item 16. Exhibits and Financial Statement Schedules
Page 227 - provided
Page 228 - SIGNATURES
Page 229 - N/A
Page 230 - EXHIBIT INDEX
Page 231 - N/A
Subdocument 2 - EX-10.2 - EX-10.2
Page 1 - Exhibit 10.2
Page 2 - TABLE OF CONTENTS
Page 3 - N/A
Page 4 - VITAE PHARMACEUTICALS, INC. 2001 STOCK PLAN
Page 5 - SECTION 4. STOCK SUBJECT TO PLAN
Page 6 - SECTION 6. TERMS AND CONDITIONS OF OPTIONS
Page 7 - (k)
Page 8 - (e)
Page 9 - (c)
Page 10 - SECTION 10. NO RETENTION RIGHTS
Page 11 - Code
Page 12 - Outside Director
Page 13 - Section 13 of the Stock Option Agreement includes important acknowledgements of the Optionee
Page 14 - SECTION 2.
Page 15 - SECTION 5.
Page 16 - Death of the Optionee
Page 17 - SECTION 7.
Page 18 - SECTION 10.
Page 19 - Legends
Page 20 - SECTION 12.
Page 21 - SECTION 14.
Page 22 - ISO
Page 23 - Transferee
Page 24 - N/A
Page 25 - Section 13 of the Stock Option Agreement includes important acknowledgements of the Optionee
Page 26 - THE OPTION GRANTED PURSUANT TO THIS AGREEMENT AND THE SHARES ISSUABLE UPON THE EXERCISE THEREOF HAVE
Page 27 - SECTION 4.
Page 28 - SECTION 6.
Page 29 - bona fide
Page 30 - Assignment of Right of First Refusal
Page 31 - Investment Intent at Grant
Page 32 - Removal of Legends
Page 33 - Choice of Law
Page 34 - Consultant
Page 35 - Plan
Subdocument 3 - EX-10.24 - EX-10.24
Page 1 - Exhibit 10.24
Page 2 - Permitted Prepayment of Term Loan
Page 3 - 2.4 Fees.
Page 4 - 3.2 Conditions Precedent to all Credit Extensions.
Page 5 - 4 CREATION OF SECURITY INTEREST
Page 6 - 5.7 Subsidiaries; Investments.
Page 7 - 6.1 Government Compliance.
Page 8 - 6.4 Taxes; Pensions.
Page 9 - 6.7 Protection of Intellectual Property Rights.
Page 10 - N/A
Page 11 - Event of Default
Page 12 - N/A
Page 13 - N/A
Page 14 - Communication
Page 15 - TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, BORROWER, LENDERS AND COLLATERAL AGENT EACH WAIVE
Page 16 - N/A
Page 17 - N/A
Page 18 - Account
Page 19 - Borrower s Books
Page 20 - Commodity Account
Page 21 - Equipment
Page 22 - Loan Payment/Advance Request Form
Page 23 - Permitted Investments
Page 24 - but
Page 25 - Requirement of Law
Page 26 - EXHIBIT A
Page 27 - EXHIBIT B
Page 28 - BORROWER:
Page 29 - EXHIBIT C -COMPLIANCE CERTIFICATE
Page 30 - N/A
Page 31 - EXHIBIT D
Page 32 - N/A
Page 33 - EXHIBIT E
Page 34 - N/A
Page 35 - N/A
Page 36 - N/A
Page 37 - N/A
Subdocument 4 - EX-23.1 - EX-23.1
Page 1 - Exhibit 23.1
Page 2 - N/A